Nightingale Health expands service coverage to the United States
To enhance services for its global customer base, Nightingale Health, the innovator of an award-winning biomarker analysis technology, has expanded its operational capacity to receive and process samples within the United States. The new regional service, available through PerkinElmer Genomics’ CLIA and CAP-certified clinical laboratory in Pittsburgh, removes the necessity to transport samples to the European Union, with all sample handling, shipping and analysis being carried out domestically.
By increasing the availability of its services in the U.S., Nightingale can facilitate metabolic analyses at a previously unprecedented scale; accommodating biobanks, national health initiatives and large sample collections. The news enables closer cooperation with local partners and represents a further step towards fully integrating Nightingale’s blood analysis technology into global clinical practice.
“Nightingale has been involved in some of the world’s largest metabolomics projects, including being selected to analyse the entire UK Biobank cohort of 500 000 samples, the national biobank of Finland (THL Biobank) and the Mexico City Prospective Cohort in coordination with Oxford University. We’re now looking to expand the use of our platform with ground-breaking initiatives in the U.S., and further enhance public health research with large studies worldwide,” says Dr. Peter Würtz, Scientific Director and Co-founder at Nightingale Health.
“We are pleased that Nightingale selected our clinical laboratory in Pittsburgh to expand its innovative biomarker analysis offering to customers here in the U.S.,” said Dr. Madhuri Hegde, Vice President and Chief Scientific Officer, PerkinElmer Genomics.
By measuring a person’s comprehensive health state using a single blood sample, Nightingale equips biomedical researchers with insights into the effects of lifestyle factors and future disease risk – accelerating breakthroughs in life sciences research and chronic disease prevention. Nightingale’s technology and services have a wide range of medical applications, with customers including world-leading research institutions, pharma, healthcare providers and consumers.
More information:
Nightingale’s biomarker analysis service for blood, cord blood, urine and cerebrospinal fluid for researchers, pharma and healthcare providers.
Teemu Suna
Founder, CEO
Nightingale Health
p. +358 40 196 1669
press@nightingalehealth.com
Tuija Arola
Head of Research Solutions
tuija.arola@nightingalehealth.com
About Nightingale Health
Nightingale Health is a Finnish biotech company and the innovator of an award-winning biomarker analysis technology. By measuring the comprehensive health state from a person using a single blood sample, Nightingale equips biomedical researchers with insights into the effects of lifestyle factors and future disease risk, accelerating breakthroughs in chronic disease prevention. The company is investing and working towards integrating its technology into clinical practice to bring about precision medicine – empowering patients to follow up on their own well-being and take proactive steps to stay healthy.
For more information on Nightingale, please visit www.nightingalehealth.com
Tags:
